Table 2. Study-level estimates of transmitted drug resistance in seven geo-economic regions.

TDR	SSA (n = 95)	SSEA (n = 56)	Latin America/Caribbean (n = 38)	Europe (n = 42)	North America (n = 27)	Upper-Income Asia (n = 12)	FSU (n = 12)
Overall	2.8% (1.3%–5.6%)	2.9% (1.8%–5.3%)	7.6% (3.9%–10.2%)	9.4% (6.1%–15.1%)	11.5% (8.3%–14.6%)	5.6% (3.5%–9.0%)	4.0% (0%–6.4%)
NRTI	0% (0%–2.4%)	1% (0%–2.4%)	4% (1.8%–6.6%)	5.6% (3.1%–10.1%)	5.8% (3.4%–8.2%)	3.5% (1.5%–5.0%)	1.8% (0%–3.9%)
NNRTI	1.4% (0%–2.8%)	0.8% (0%–2.1%)	2.8% (1.1%–5.0%)	3.4% (1.5%–5.3%)	4.5% (3.0%–6.8%)	1.1% (0.2%–1.6%)	0.8% (0%–2.1%)
PI	0% (0%–1.4%)	0.5% (0%–1.9%)	1.4% (0%–3.0%)	1.5% (0%–2.8%)	3.0% (2.3%–3.9%)	1.6% (0.6%–3.0%)	0.2% (0%–2.1%)

Data are median (IQR) of study-level prevalence of individuals with any (overall) and NRTI-, NNRTI-, and PI-associated SDRMs by region; the number of studies conducted is indicated for each region (n). Latin America/Caribbean includes three studies from Caribbean countries. Three studies from North Africa and two studies from Australia are not included in this table but are summarized in S1 Table.